Patient Reported Outcomes in Patients with Newly Diagnosed FLT3 mut+ acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI